$9.76
−7.72 (−44.16%)Oct 28, 2026, 8:00 PM ET
Market Closed
Video Interviews
View All Interviews →Building a High-Grade Gold Asset at a Nevada Location
Apr 20, 2026
Company Overview
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Key Highlights
- Biotechnology · Healthcare
- Led by Claire Mazumdar Clemon
- 103 employees
- Based in Boston, MA
Analyst Coverage
View All Coverage →No analyst coverage available.
Economic Calendar
View more →- Oct 28
FOMC Meeting
2:00 PM ET
- Oct 28
FOMC Rate Decision
2:00 PM ET
- Oct 28
FOMC Press Conference
2:30 PM ET
- Oct 29
Initial Jobless Claims
8:30 AM ET
Crypto Prices
View more →
Bitcoin (BTC)
81,277 +0.56%
Stock Quote
View Full Quote →NASDAQ:BCAX
Bicara Therapeutics Inc. Common Stock
$9.76
−7.72 (−44.16%)- Day Range
- $8.90 – $17.57
- 52 Week Range
- 8.9-30.99
- Volume
- 15,376,724
- Avg. Volume
- 746,290
- Market Cap
- 645.8M
- Shares Outstanding
- —
Market data delayed by 15 minutes.
Company Facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, US
- Incorporated
- Sep 13, 2024
- Website
